Inhibitors of bromodomain and extra‐terminal proteins for treating multiple human diseases

por Kulikowski, Ewelina, Rakai, Brooke D., Wong, Norman C. W.
Publicado 2020

Downregulation of the Complement Cascade In Vitro, in Mice and in Patients with Cardiovascular Disease by the BET Protein Inhibitor Apabetalone (RVX-208)

por Wasiak, Sylwia, Gilham, Dean, Tsujikawa, Laura M., Halliday, Christopher, Calosing, Cyrus, Jahagirdar, Ravi, Johansson, Jan, Sweeney, Michael, Wong, Norman C., Kulikowski, Ewelina
Publicado 2017

APABETALONE (RVX-208) REDUCES ACE2 PROTEIN ABUNDANCE AND PREVENTS SARS-COV-2 SPIKE PROTEIN BINDING TO HUMAN LUNG CELLS, A MOA THAT COULD ATTENUATE VIRAL ENTRY

por Fu, Li, Gilham, Dean, Tsujikawa, Laura, Rakai, Brooke D., Wasiak, Sylwia, Stotz, Stephanie, Sarsons, Christopher D., Sweeney, Michael, Johansson, Jan, Wong, Norman, Kulikowski, Ewelina
Publicado 2021

Benefit of Apabetalone on Plasma Proteins in Renal Disease

por Wasiak, Sylwia, Tsujikawa, Laura M., Halliday, Christopher, Stotz, Stephanie C., Gilham, Dean, Jahagirdar, Ravi, Kalantar-Zadeh, Kamyar, Robson, Richard, Sweeney, Michael, Johansson, Jan O., Wong, Norman C., Kulikowski, Ewelina
Publicado 2017

Inhibition of epigenetic reader proteins by apabetalone counters inflammation in activated innate immune cells from Fabry disease patients receiving enzyme replacement therapy

por Fu, Li, Wasiak, Sylwia, Tsujikawa, Laura M., Rakai, Brooke D., Stotz, Stephanie C., Wong, Norman C. W., Johansson, Jan O., Sweeney, Michael, Mohan, Connie M., Khan, Aneal, Kulikowski, Ewelina
Publicado 2022

Dual mechanism: Epigenetic inhibitor apabetalone reduces SARS-CoV-2 Delta and Omicron variant spike binding and attenuates SARS-CoV-2 RNA induced inflammation

por Fu, Li, Gilham, Dean, Stotz, Stephanie C., Sarsons, Christopher D., Rakai, Brooke D., Tsujikawa, Laura M., Wasiak, Sylwia, Johansson, Jan O., Sweeney, Michael, Wong, Norman C.W., Kulikowski, Ewelina
Publicado 2023

Apabetalone and hospitalization for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE study

por Nicholls, Stephen J., Schwartz, Gregory G., Buhr, Kevin A., Ginsberg, Henry N., Johansson, Jan O., Kalantar-Zadeh, Kamyar, Kulikowski, Ewelina, Toth, Peter P., Wong, Norman, Sweeney, Michael, Ray, Kausik K.
Publicado 2021

Relation of insulin treatment for type 2 diabetes to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE randomized clinical...

por Schwartz, Gregory G., Nicholls, Stephen J., Toth, Peter P., Sweeney, Michael, Halliday, Christopher, Johansson, Jan O., Wong, Norman C. W., Kulikowski, Ewelina, Kalantar-Zadeh, Kamyar, Ginsberg, Henry N., Ray, Kausik K.
Publicado 2021

Data on gene and protein expression changes induced by apabetalone (RVX-208) in ex vivo treated human whole blood and primary hepatocytes

por Wasiak, Sylwia, Gilham, Dean, Tsujikawa, Laura M., Halliday, Christopher, Norek, Karen, Patel, Reena G., McLure, Kevin G., Young, Peter R., Gordon, Allan, Kulikowski, Ewelina, Johansson, Jan, Sweeney, Michael, Wong, Norman C.
Publicado 2016

Epigenetic Modulation by Apabetalone Counters Cytokine-Driven Acute Phase Response In Vitro, in Mice and in Patients with Cardiovascular Disease

por Wasiak, Sylwia, Gilham, Dean, Daze, Emily, Tsujikawa, Laura M., Halliday, Christopher, Stotz, Stephanie C., Rakai, Brooke D., Fu, Li, Jahagirdar, Ravi, Sweeney, Michael, Johansson, Jan O., Wong, Norman C. W., Kulikowski, Ewelina
Publicado 2020

Bromodomain and Extraterminal Protein Inhibitor, Apabetalone (RVX-208), Reduces ACE2 Expression and Attenuates SARS-Cov-2 Infection In Vitro

por Gilham, Dean, Smith, Audrey L., Fu, Li, Moore, Dalia Y., Muralidharan, Abenaya, Reid, St. Patrick M., Stotz, Stephanie C., Johansson, Jan O., Sweeney, Michael, Wong, Norman C. W., Kulikowski, Ewelina, El-Gamal, Dalia
Publicado 2021

BET protein inhibitor apabetalone (RVX-208) suppresses pro-inflammatory hyper-activation of monocytes from patients with cardiovascular disease and type 2 diabetes

por Wasiak, Sylwia, Dzobo, Kim E., Rakai, Brooke D., Kaiser, Yannick, Versloot, Miranda, Bahjat, Mahnoush, Stotz, Stephanie C., Fu, Li, Sweeney, Michael, Johansson, Jan O., Wong, Norman C. W., Stroes, Erik S. G., Kroon, Jeffrey, Kulikowski, Ewelina
Publicado 2020

Reduction in the risk of major adverse cardiovascular events with the BET protein inhibitor apabetalone in patients with recent acute coronary syndrome, type 2 diabetes, and modera...

por Toth, Peter P., Schwartz, Gregory G., Nicholls, Stephen J., Khan, Aziz, Szarek, Michael, Ginsberg, Henry N., Johansson, Jan O., Kalantar-Zadeh, Kamyar, Kulikowski, Ewelina, Lebioda, Ken, Wong, Norman C.W., Sweeney, Michael, Ray, Kausik K.
Publicado 2022

RVX-208, an Inducer of ApoA-I in Humans, Is a BET Bromodomain Antagonist

por McLure, Kevin G., Gesner, Emily M., Tsujikawa, Laura, Kharenko, Olesya A., Attwell, Sarah, Campeau, Eric, Wasiak, Sylwia, Stein, Adam, White, Andre, Fontano, Eric, Suto, Robert K., Wong, Norman C. W., Wagner, Gregory S., Hansen, Henrik C., Young, Peter R.
Publicado 2013

Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism

por Tsujikawa, Laura M., Fu, Li, Das, Shovon, Halliday, Christopher, Rakai, Brooke D., Stotz, Stephanie C., Sarsons, Christopher D., Gilham, Dean, Daze, Emily, Wasiak, Sylwia, Studer, Deborah, Rinker, Kristina D., Sweeney, Michael, Johansson, Jan O., Wong, Norman C. W., Kulikowski, Ewelina
Publicado 2019

Cognitive Effects of the BET Protein Inhibitor Apabetalone: A Prespecified Montreal Cognitive Assessment Analysis Nested in the BETonMACE Randomized Controlled Trial

por Cummings, Jeffrey, Schwartz, Gregory G., Nicholls, Stephen J., Khan, Aziz, Halliday, Chris, Toth, Peter P., Sweeney, Michael, Johansson, Jan O., Wong, Norman C.W., Kulikowski, Ewelina, Kalantar-Zadeh, Kamyar, Lebioda, Kenneth, Ginsberg, Henry N., Winblad, Bengt, Zetterberg, Henrik, Ray, Kausik K.
Publicado 2021

Would integrated Western and traditional Chinese medicine have more benefits for stroke rehabilitation? A systematic review and meta-analysis

por Zhong, Linda LD, Zheng, Ya, Lau, Alexander Y, Wong, Norman, Yao, Liang, Wu, Xingyao, Shao, Tengteng, Lu, Zhenxing, Li, Huijuan, Yuen, Chun Sum, Guo, Jianwen, Lo, Suzanne, Chau, Janita, Chan, Kam Wa, Ng, Bacon Fung Leung, Bian, Zhaoxiang, Yu, Edwin Chau-leung
Publicado 2021

BET inhibition blocks inflammation-induced cardiac dysfunction and SARS-CoV-2 infection

por Mills, Richard J., Humphrey, Sean J., Fortuna, Patrick R.J., Lor, Mary, Foster, Simon R., Quaife-Ryan, Gregory A., Johnston, Rebecca L., Dumenil, Troy, Bishop, Cameron, Rudraraju, Rajeev, Rawle, Daniel J., Le, Thuy, Zhao, Wei, Lee, Leo, Mackenzie-Kludas, Charley, Mehdiabadi, Neda R., Halliday, Christopher, Gilham, Dean, Fu, Li, Nicholls, Stephen J., Johansson, Jan, Sweeney, Michael, Wong, Norman C.W., Kulikowski, Ewelina, Sokolowski, Kamil A., Tse, Brian W.C., Devilée, Lynn, Voges, Holly K., Reynolds, Liam T., Krumeich, Sophie, Mathieson, Ellen, Abu-Bonsrah, Dad, Karavendzas, Kathy, Griffen, Brendan, Titmarsh, Drew, Elliott, David A., McMahon, James, Suhrbier, Andreas, Subbarao, Kanta, Porrello, Enzo R., Smyth, Mark J., Engwerda, Christian R., MacDonald, Kelli P.A., Bald, Tobias, James, David E., Hudson, James E.
Publicado 2021